RAP
Director Trades
| Date | Director | Value |
|---|
Company News
ResApp Health’s takeover bid from Pfizer shaved by $53m after disappointing study results
ResApp Health’s (ASX: RAP) shares sank 30% this week after the company announced less than impressive study results on its COVID-19 cough detection app, which has resulted in $53 million being immediately erased from Pfizer’s proposed takeover bid. The Queensland-based digital health firm caught Pfizer’s attention in April, when a March pilot study of the […]
ResApp Health unveils at-home sleep apnoea screening app
Digital health company ResApp Health (ASX: RAP) has unveiled a new smartphone app that can be used in the home to assess a person’s risk of obstructive sleep apnoea. According to ResApp, the SleepCheck app uses clinically accurate algorithms to analyse the consumer’s breathing and snoring sounds during sleep. The app does not require any […]
ResApp and Coviu team up to provide remote respiratory tests through telehealth platform
Digital health company ResApp Health (ASX: RAP) has inked a binding deal to integrate its ResAppDx-EU diagnostic test into Coviu’s telehealth platform to enable clinicians to perform respiratory assessments remotely. ResAppDx-EU is a smartphone-based acute respiratory disease diagnostic test that uses machine learning algorithms to analyse a patient’s cough sounds to diagnose lower respiratory tract […]
ResApp Health locks-in Australian TGA approval for smartphone respiratory diagnostic technology in adults
ResApp Health (ASX: RAP) has finally locked-in Australian Therapeutic Goods Administration for using its smartphone-based diagnostic technology to determine respiratory disease in adults. This latest milestone follows TGA approval in October to use its respiratory diagnostic technology in paediatrics. ResApp’s smartphone application ResAppDx-EU version two can now be used to diagnose respiratory disease in both […]
ResApp Health’s respiratory diagnostic test to be integrated into Australian telehealth platform
ResApp Health (ASX: RAP) has entered an agreement to have its acute respiratory diagnostic test integrated into Australia’s leading telehealth software platform Coviu. According to ResApp, the integration of its diagnostic technology ResAppDx-EU into Coviu will see it made available to more than 5,500 clinicians across 1,000 clinics who currently use the platform. Coviu is […]
ResApp to take part in German digital health program, secures TGA approval
Digital health company ResApp Health (ASX: RAP) has been given an operational boost by a German health program backed by pharmaceutical giants Roche and Sanofi, while also securing Therapeutic Goods Administration approval for its respiratory diagnostic technology in paediatrics. Earlier today, ResApp said it had been selected to join the Startup Creasphere Digital Health Program in Munich […]
ResApp Health receives positive results from at-home sleep apnoea study
Digital health company ResApp Health (ASX: RAP) has updated the market with positive top-line results from its prospective, blinded at-home obstructive sleep apnoea study that included 308 patients. Sleep apnoea is a common sleep disorder where the person repeatedly stops breathing or has periods of shallow breathing during sleep. As things stand, nearly 1 billion people […]
ResApp Health can now market respiratory diagnostic technology for adults in EU
ResApp Health (ASX: RAP) has received Europe’s CE Mark approval for its latest smartphone-based respiratory disease diagnostic test for adults and children, paving the way for the company to sell the test throughout the region. CE Mark approval for ResApp’s ResAppDx-EU version two test builds on the existing CE approval for the original ResAppDX-DU test, […]
ResApp gets all-clear to market respiratory disease test in Europe
Digital health innovator ResApp Health (ASX: RAP) has received a significant boost courtesy of European regulatory approval for its first commercial product, ResAppDx-EU. The smartphone app has received CE Mark certification as a Class 2a medical device thereby validating and securing its future marketability as a diagnostic test for acute paediatric respiratory disease. Obtaining CE […]
ResApp Health bounces back with ‘positive top-line results’ in adult respiratory disease study
ResApp Health (ASX: RAP) has reported “positive top-line results” from an adult clinical study, with the company’s smartphone app able to accurately diagnose all lower respiratory tract diseases evaluated in the study. Today’s positive news follows preliminary results from a trial evaluating the efficacy of the app in childhood acute respiratory diseases in late October […]
Company Videos
No videos found.